Event Radar

2026 Revenue Guidance Revised, Platform Profitability Guidance Reaffirmed&#59; That is why we lowered our revenue guidance while reaffirming our Platform Adjusted EBITDA guidance."

Rallybio Corporation (the "Company") announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of May 31, 2026, by and among the Company, Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc., will close following the close of trading on November 20, 2026. The Company received approval from the Listing Qualifications department of The Nasdaq Stock Market to list its common stock on the Nasdaq Capital Market in connection with the Merger.

SIDU: Accounting restatement

Amounts payable under the 2027 OIP that exceed 100 percent of the target amount could be paid in full, or in part, in the form of restricted stock units ("RSUs") and/or Deferred Retention Stock Units ("DRSUs") based on the President and Chief Executive Officer’s recommendation and subsequent approval by the LDCC, or in the case of the President and Chief Executive Officer, based on the LDCC’s determination.

Together with our lower operating expenses, that gives us a leaner cost base and a cleaner balance sheet as we execute against our revised full-year outlook."

• Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus In October, Bolt completed its acquisition of Prana Therapies in a sign-and-close, stock-for-stock reverse merger and closed a concurrent $120 million private placement financing with leading healthcare institutional investors.

The closing of the early-stage HbF assets sale is contingent upon consummation of the proposed merger pursuant to that certain Merger Agreement dated August 16, 2026, by and among Fulcrum, Fusion Merger Sub I, Fusion Merger Sub II and Slate, or the Merger Agreement (or in the event the Merger Agreement is terminated, upon receipt of any necessary approvals). Fulcrum expects that the proceeds from the asset sale will be funded into escrow prior to the closing of the proposed merger and will be credited to Fulcrum’s net cash for purposes of the Merger Agreement and increase the amount of cash dividend expected to be declared in connection with the proposed merger.

Such risks, uncertainties and assumptions include, but are not limited to: (1) our ability to maintain our key relationships with network partners and advertisers, including our monetization arrangements&#59; (2) our ability to collect, process, effectively utilize and safely store the first party data that we obtain through our services&#59; (3) the performance of our marketing platform&#59; (4) changes in customer demand for our services and our ability to quickly adapt to such changes&#59; (5) our ability to maintain and attract consumers and advertisers in the face of changing economic

Amendment No. 1 to Agreement and Plan of Merger On November 6, 2026, GoPro, Inc., a Delaware corporation (the "Company"), entered into Amendment No. 1 (the "Amendment") to the Agreement and Plan of Merger, dated as of September 1, 2026 (as amended, the "Merger Agreement"), by and among Action Acquisition LLC, a Delaware limited liability company ("Parent"), Starman Optical, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and the Company.

NVDA: CEO exit

On November 11, 2026, the Board of Directors, or the Board, of NVIDIA Corporation accepted the resignation of Jen-Hsun Huang, as NVIDIA’s President, Chief Executive Officer and member of the Board, effective immediately.

Agreement and Plan of Merger On November 11, 2026, BCP Investment Corporation, a Delaware corporation (" BCIC "), entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Investcorp Credit Management BDC, Inc., a Maryland corporation (" ICMB "), and Aria Acquisition Sub, Inc., a Maryland corporation and a direct wholly-owned subsidiary of BCIC (" Acquisition Sub ").

Cortigent-ClearOne merger is awaiting final regulatory approvals allowing establishment of Cortigent as a standalone company trading on the Nasdaq under ticker symbol CRGT On October 30, 2026, the Company filed an current report on Form 8-K with the U.S. Securities and Exchange Commission to clarify that the expected close of the of the Cortigent merger remains subject to final regulatory approval and is expected to close shortly after approval is received.

On November 12, 2026, Trustmark Corporation ("Trustmark"), parent company of Trustmark Bank, and Hancock Whitney Corporation ("Hancock Whitney"), parent company of Hancock Whitney Bank, issued a joint press release announcing the execution of the Agreement and Plan of Merger, dated as of November 11, 2026, by and between Hancock Whitney and Trustmark pursuant to which, upon the terms and subject to the conditions set forth therein, Trustmark will merge with and into Hancock Whitney, with Hancock Whitney continuing as the surviving corporation. The acquisition is expected to close late in the first quarter of 2027, subject to the receipt of regulatory approvals, shareholder approvals and the satisfaction of other customary closing conditions.

PROF: CEO exit

as of the Transition Date, and Arun Menawat will step down as Chief Executive Officer and will become Executive Chairman of the Board

On November 12, 2026, Hancock Whitney Corporation ("Hancock Whitney") parent company of Hancock Whitney Bank, and Trustmark Corporation ("Trustmark"), parent company of Trustmark Bank, issued a joint press release announcing the execution of the Agreement and Plan of Merger, dated as of November 11, 2026 by and between Hancock Whitney and Trustmark pursuant to which, upon the terms and subject to the conditions set forth therein, Trustmark will merge with and into Hancock Whitney, with Hancock Whitney continuing as the surviving corporation. The acquisition is expected to close late in the first quarter of 2027, subject to the receipt of regulatory approvals, shareholder approvals and the satisfaction of other customary closing conditions.

notified Cohen & Company Inc., a Maryland corporation (the "Company"), of his decision to resign as Chief Executive Officer

• Entered into a definitive merger agreement with technology and software expert, Thoma Bravo with an expected closing in the first half of 2027

‒ Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance ‒ • The Company maintains full-year 2026 consolidated revenue guidance of $325 to $345 million, narrows full-year adjusted EBITDA guidance to a range of $130 to $140 million from a range of $125 to $140 million, and reduces cash-based OpEx guidance to a range of $140 to $145 million from $145 to $155 million.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from those expressed in or implied by the forward-looking statements, including (1) our ability to sustain our growth, effectively manage our anticipated future growth, and implement our business strategies to achieve the results we anticipate, (2) our current liquidity resources raise substantial doubt about our ability to continue as a going concern, (3) impairments of our intangible assets and equity method investment in our joint ventures, (4) our ability to raise additional capital,

The investor presentation furnished as Exhibit 99.2 to this Current Report on Form 8-K includes, in addition to the Company’s third quarter 2026 results, forward-looking information regarding the Company’s full-year 2026 guidance, strategic priorities, new product and geographic expansion initiatives, and business outlook. Capstone now expects FY2026 revenue of approximately $70 million, gross profit of approximately $18.6 million and Stone Business Adjusted EBITDA of approximately $3.2 to 3.3 million, compared with its prior guidance of $72.1 million, $18.7 million and $3.8 million, respectively.

ADI Announces Third Quarter 2026 Financial Results and Updates Full-Year Outlook • Updates full-year 2026 financial guidance

"This transformative merger brings together two complementary platforms across different therapeutic modalities and has significant upside potential through Castle Creek’s fibroblast-based cell and gene therapy technology, and its lead candidate, D-Fi, which has the potential to become a blockbuster franchise in dystrophic epidermolysis bullosa, or DEB. On October 30, 2026, the Company announced that it entered into a definitive merger agreement under which Castle Creek Biosciences, Inc. ("Castle Creek"), a late-stage company developing redosable gene therapies, will merge into an affiliate of Pelthos via a series of mergers.

Guidance on Core Operations

Amendment to Hughes Brothers Merger Agreement As previously reported, on October 13, 2026, Cardinal Infrastructure Group Inc. ("Cardinal" or the "Company") entered into an Agreement and Plan of Merger (the "Original Merger Agreement") by and among Cardinal, CHBC Intermediate Holdco, Inc., a Delaware corporation and wholly owned subsidiary of Cardinal ("Merger Sub 1"), CHBC Holding Company, LLC, a Delaware limited liability company and wholly owned subsidiary of Cardinal ("Merger Sub 2"), HBC Holdco, Inc., a Delaware corporation ("Target"), Hughes Brothers Construction Inc., a Florida corporation ("HBC"), the stockholders of HBC party ther

Record third quarter revenue and Adjusted EBITDA exceed outlook&#59; 2026 outlook 1 updated to include revenue growth of approximately 37% and Adjusted EBITDA growth of approximately 37% "Revenue and Adjusted EBITDA reached record levels and exceeded the outlook we provided last quarter.

Saturday, November 7, 2026, Air Industries Group (the "Company") received a letter from Tenax Aerospace Acquisition, LLC Restated Agreement and Plan of Merger dated July 2, 2026, as amended.

IRON HORSE ACQUISITION II CORP. On November 10, 2026, Iron Horse Acquisition II

NMAD: CEO exit

Departure of Chief Executive Officer

Similarly, statements that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding, and the guidance we give with respect to, our anticipated operating or financial results, future financial performance and outlook, future dividend declarations, and future economic conditions.

subsidiary of Archrock, Inc., a Delaware corporation (" Archrock "), entered into an Agreement and Plan of Merger (the " Merger Agreement ") by and among the Company, Project Avengers 2026 Merger Sub, LLC, a wholly owned subsidiary

result in the failure to meet a closing condition of the Company’s pending merger and permit the acquirer to terminate the merger agreement.

– Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing The Company continues to advance its proposed merger (the "Merger") with Avere Therapeutics, Inc., a privately held biotechnology company focused on oral therapies for IL-23-driven inflammatory diseases ("Avere"), which is now supported by approximately $820 million of committed financing from a syndicate of leading healthcare-focused and institutional investors.

2026 Full Year Outlook: update on its guidance for the full year ended December 31, 2026.

• Reaffirms 2026 Revenue Guidance; Revises 2026 Gross Margin Guidance; Reduces 2026 Capital Expenditures Guidance; Now Expects Positive Net Cash from Operations in 2028

Based on this solid execution, we are raising our outlook for fiscal year 2027." ET on Tuesday, November 10, 2026, to discuss Mercury's quarterly financial results, business highlights and outlook.

Industries (the "Company"), a Delaware corporation, entered into an Agreement and Plan of Merger (the "Merger Agreement") with Patrick Industries, Inc. ("Patrick"), an Indiana corporation, Planet First Merger Sub Inc., a newly formed Delaware corporation

continuing operations and the substantial doubt about its ability to continue as a going concern; the Company's ability to obtain additional

MERC: Bankruptcy

expects that this financing will alleviate the substantial doubt of continuing as a going concern as previously identified in prior reporting

GTEN: Accounting restatement

(e) On November 9, 2026, AGNT, Inc. (the "Company"), and Glenn Sanford, the Company’s founder, former Chief Executive Officer and currently a member and Chairman of the Company’s Board of Directors (the "Board"), entered into a Termination and Release Agreement (the "Termination Agreement"), effective retroactively as of October 8, 2026 (the "Separation Date"), the date on which Mr. Sanford’s employment with the Company and its subsidiaries ended in connection with the previously announced Chief Executive Officer transition described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 8, 2026 (the "Prior 8-K").

Mr. K. Newton’s transition from Chief Executive Officer (i) is not a termination of employment or service for purposes of his outstanding equity awards and (ii) does not constitute "Good Reason" under the K.

Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance Lakewood, Colorado , November 9, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced results for its second fiscal quarter ("2Q27") ended September 30, 2026, and issued full-year guidance for the first time (dollars in thousands, except per-share amounts).

• Factors that could cause the Company’s results to differ materially from those expressed in forward - looking statements include, without limitation, substantial doubt about the Company’s ability to continue as a going concern and its need for additional capital, which may not be available on acceptable terms or at all ; the Phase 3 TransportNPC study did not meet its primary endpoint, and the FDA may not accept the remibetadex NDA for filing, grant priority review or approve it ; remibetadex may not be eligible for, or receive, a rare pediatric disease priority review voucher ; the Co